TY - JOUR
T1 - Outcome of allogeneic transplantation for mature T-cell lymphomas
T2 - impact of donor source and disease characteristics
AU - Hamadani, Mehdi
AU - Ngoya, Maud
AU - Sureda, Anna
AU - Bashir, Qaiser
AU - Litovich, Carlos Alejandro
AU - Finel, Herve
AU - Chen, Yue
AU - Boumendil, Ariane
AU - Zain, Jasmine
AU - Castagna, Luca
AU - Cashen, Amanda F.
AU - Blaise, Didier
AU - Shadman, Mazyar
AU - Pastano, Rocco
AU - Khimani, Farhad
AU - Arat, Mutlu
AU - Dietrich, Sascha
AU - Schmitz, Norbert
AU - Glass, Bertram
AU - Kharfan-Dabaja, Mohamed A.
AU - Corradini, Paolo
AU - Sauter, Craig S.
AU - Montoto, Silvia
AU - Kwon, Mi
AU - Herrera, Alex F.
AU - Dreger, Peter
N1 - Publisher Copyright:
© 2022 by The American Society of Hematology.
PY - 2022/2/8
Y1 - 2022/2/8
N2 - Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamide-based haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD1), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD2). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD1; 326 MUD TCD2). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group.
AB - Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamide-based haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD1), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD2). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD1; 326 MUD TCD2). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group.
UR - http://www.scopus.com/inward/record.url?scp=85124235616&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021005899
DO - 10.1182/bloodadvances.2021005899
M3 - Article
C2 - 34861680
AN - SCOPUS:85124235616
SN - 2473-9529
VL - 6
SP - 920
EP - 930
JO - Blood Advances
JF - Blood Advances
IS - 3
ER -